

AMENDMENT

Please amend the application without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

In the Claims

Please cancel claims 19-24 and 34, amend claims 1, 8, and 35, and add new claim 36 as follows:

1. (Currently amended) A conjugate comprising a first sequence and a second sequence, wherein the first sequence comprises a protein an antibody or antibody fragment which binds to an antigen presenting cell (APC), and wherein the second sequence comprises a Notch ligand or a fragment thereof, which retains Notch signalling activity wherein the second sequence comprises a Notch ligand DSL domain and at least one EGF-like repeat, and wherein the second sequence retains Notch signalling activity.

2. (Original) The conjugate according to claim 1, wherein the conjugate is a fusion protein.

3-7. (Cancelled)

8. (Currently amended) The conjugate according to claim 1, wherein the second sequence is from a Notch ligands ligand selected from the group consisting of Delta, Jagged, [or] and Serrate.

9-17. (Cancelled)

18. (Previously presented) The conjugate according to claim 1, wherein the first sequence is a protein which binds to an MHC class II molecule.

19-28. (Cancelled)

29. (Previously presented) A conjugate prepared by

(a) transforming a host cell with an expression vector comprising a polynucleotide sequence encoding the conjugate of claim 1; and

(b) culturing the host cell under conditions which provide for expression of the conjugate.

30. (Withdrawn) A method of targeting a protein for Notch signalling modulation, or a polynucleotide coding therefor, to an APC comprising exposing the APC to the conjugate according to claim 1.

31. (Original) A composition comprising the conjugate of claim 1 and a pharmaceutically acceptable excipient, diluent or carrier.
32. (Withdrawn) A method of preventing or treating a disease or infection a subject in need thereof, comprising administering the conjugate according to claim 1 to the subject.
33. (Withdrawn) The method according to claim 32, wherein the disease is a T-cell mediated disease.
34. (Cancelled)
35. (Currently amended) The conjugate according to claim [[34]] 1, wherein the first sequence comprises a protein which binds to an APC surface molecule, wherein the APC surface molecule is selected from the group consisting of an MHC class II molecule, CD205 (DEC205), CD204, CD14, CD206, TLRs, Langerin (CD207), DC-SIGN (CD209), CD32, CD68, CD83, CD33, CD54 and BDCA-2,3,4.
36. (New) The conjugate according to claim 1, wherein the second sequence is a human Notch ligand selected from the group consisting of human Delta 1 comprising the amino acid sequence of SEQ ID NO: 40, human Delta 3 comprising the amino acid sequence of SEQ ID NO: 41, human Delta 4 comprising the amino acid sequence of SEQ ID NO: 42, human Jagged 1 comprising the amino acid sequence of SEQ ID NO: 43, Jagged 2 comprising the amino acid sequence of SEQ ID NO: 44, or a human Notch ligand fragment selected from the group consisting of the amino acid sequence of SEQ ID NO: 25, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 36, SEQ ID NO: 38 and SEQ ID NO: 39.